2024-11-0920221558-767310.1016/j.clgc.2021.09.0072-s2.0-85118833159http://dx.doi.org/10.1016/j.clgc.2021.09.007https://hdl.handle.net/20.500.14288/12834Deciding on the management of prostate cancer (PCa), especially GG1 PCa, is quite difficult. The most important thing that will help us in making active surveillance or definitive treatment decision is whether the tumor is a clinically significant tumor. To understand this, we discussed in this article that multiparametric MR, PI-RADS scoring and targeted biopsy can be used. BackgroundOncologyUrologyNephrologyJournal Article1938-06827912219000166369